#ALS #NeuroSense #Alzheimer

NeuroSense Therapeutics to Host Investor Webinar

Date: December 3, 2025
Location: Virtual (Eastern Time)

On December 8, 2025, NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotechnology firm in the late-clinical stage, will conduct a webinar specifically for its investors. This event aims to present crucial updates regarding the company's ongoing projects and forthcoming objectives directed towards treating severe neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

The webinar will commence at 8:30 AM ET, where company executives will disclose significant milestones achieved recently and future directions. Notably, the topics will include the initiation of the Phase 3 PARAGON study for ALS, submission details for the Notice of Compliance with conditions (NOC/c) in Canada, and the status of a binding term sheet which was executed in December 2024. Furthermore, updates will be provided on the RoAD Phase 2 program aimed at Alzheimer’s treatment.

Company Overview

NeuroSense Therapeutics is dedicated to developing innovative treatment methodologies aimed at alleviating the burden of neurodegenerative diseases. The company recognizes that diseases like ALS, Alzheimer’s disease, and Parkinson’s disease significantly impact patients' lives, with very few effective therapeutic interventions available. Leveraging extensive scientific research on diverse biomarkers, NeuroSense is committed to formulating combination therapies that address multiple biological pathways involved in these debilitating conditions.

For investors aiming to attend the upcoming webinar, registration is available here. As part of their commitment to transparency and accessibility, NeuroSense emphasizes that important investor information will also be communicated through their website and social media channels such as LinkedIn, YouTube, and X.

Forward-Looking Statements

This announcement includes